| Attending joint formulation meetings on pharmaceuticals and special medical materials. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 与监管机构合作 | 100,000 | National | Sometimes | 119017792133 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance] reimbursement policies for that year. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 与监管机构合作 | 5,000 | National | Sometimes | 119022421395 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Sometimes | 119022421395 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | 神经肌肉
> 脊髓性肌萎缩症（SMA） | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100 | National | Regularly | 119053648739 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 5,000 | National | Sometimes | 119022421395 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance/Taiwan] reimbursement policies for that year. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 5,000 | National | Sometimes | 119022421395 |
| ... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome. | 癌症
> 癌症：大多数类型 | 影响政策和立法
> 影响医疗保健政策和立法 | 10,000 | National | Sometimes | 119055308347 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | 癌症
> 癌症：大多数类型 | 影响政策和立法
> 参与公众听证会和咨询 | 10,000 | National | Sometimes | 119055325391 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | 总体健康
> 医疗服务 | 定价与可负担性倡导
> 倡导公平的药品定价 | 5,000 | National | Sometimes | 119051396882 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | 癌症
> 癌症：乳腺癌 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 10,000 | National | Regularly | 119016883314 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | 总体健康
> 医疗服务 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 5,000 | National | Sometimes | 119051396882 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | 癌症
> 癌症：神经内分泌（NET） | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | National | Sometimes | 119051407743 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | 癌症
> 癌症：大多数类型 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 10,000 | National | Sometimes | 119055325391 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | 癌症
> 癌症：乳腺癌 | 改善访问路径
> 促进公平获取药品/医疗保健 | 10,000 | National | Regularly | 119016883314 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | 癌症
> 癌症：神经内分泌（NET） | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | National | Sometimes | 119051407743 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | 神经肌肉
> 脊髓性肌萎缩症（SMA） | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | National | Regularly | 119053648739 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | 癌症
> 癌症：大多数类型 | 改善访问路径
> 促进公平获取药品/医疗保健 | 10,000 | National | Sometimes | 119055308347 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | 癌症
> 癌症：大多数类型 | 循证患者意见
> 利用患者洞察来指导决策 | 5,000 | National | Sometimes | 119022421395 |
| We serve as members of the Infected Persons Rights Protection Committee under Taiwan CDC [Centers for Disease Control]. | HIV
> HIV | 机构治理
> 确保在政府咨询机构中的代表性 | 5,000 | National | Regularly | 119021698989 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | 癌症
> 癌症：大多数类型 | 机构治理
> 在多利益相关方网络中高效协作 | 10,000 | National | Sometimes | 119055308347 |
互动
行动与倡导
5 提及
